Pfizer's second quarter revenue of $15.0B beat estimates, prompting a raised FY2026 outlook.

Pfizer reported second quarter 2026 revenues of $15.0 billion and an adjusted EPS of $0.77, beating analyst expectations. On a GAAP basis, the company reported a loss of $0.04 per share, driven by $4.3 billion in intangible asset impairments. The company raised its full-year 2026 revenue guidance but reaffirmed its adjusted EPS forecast.

Key Highlights

• Excluding contributions from its COVID-19 franchise, revenues grew 5% operationally year-over-year.
• Full-year 2026 revenue guidance was raised by $500 million at the midpoint to a range of $60.5 to $62.5 billion, reflecting stronger non-COVID product performance.
• Revenue from launched and acquired products, a key growth indicator, increased 18% operationally compared to the prior-year quarter.